Citigroup Inc Pharma Cyte Biotech, Inc. Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
A detailed history of Citigroup Inc transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Citigroup Inc holds 1 shares of PMCB stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1Holding current value
$0% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PMCB
# of Institutions
28Shares Held
539KCall Options Held
10.6KPut Options Held
0-
Geode Capital Management, LLC Boston, MA127KShares$100,0160.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$72,7487.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$65,3540.09% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny80KShares$63,2000.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA74.9KShares$59,1860.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $16.4M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...